Sign in

You're signed outSign in or to get full access.

AM

Acutus Medical, Inc. (AFIB)·Q4 2024 Earnings Summary

Executive Summary

  • FY24 revenue from continuing operations reached $20.2M (+181% YoY), with sequential improvement through the year; based on FY minus 9M, Q4 revenue was approximately $7.130M, reflecting continued ramp in left-heart access manufacturing .
  • Gross margin improved materially (FY24 5% vs FY23 -44%), driven by higher production volumes and reduced manufacturing overhead; sequential margins improved Q2 (-8%) to Q3 (7%), with Q4 implied in the mid-teens by derivation .
  • The company withdrew financial guidance amid strategic realignment and a ~70% workforce reduction to support Medtronic left-heart access transition, positioning for lower cash burn and a simplified operating model (completed in Q1 2025) .
  • No Q4 earnings call transcript or Wall Street consensus (S&P Global) was available; estimate-based beat/miss analysis cannot be provided and should be considered unavailable for this period (no Q4 2024 transcript listed) and GetEstimates error.
  • Near-term stock narrative hinges on execution of downsizing, cash sufficiency, and Medtronic earn-out dynamics; FY continuing operations net loss narrowed to $4.536M (vs $11.921M in 2023), indicating improved operating leverage under the distribution-only model .

What Went Well and What Went Wrong

What Went Well

  • Material margin improvement: “Gross margin…was 5% for 2024 compared to negative 44% for 2023,” driven by “higher production volumes… and reduced manufacturing overhead expenses” .
  • OpEx discipline and operating leverage: FY operating loss was only $0.057M (vs $11.728M in 2023); sequential quarters showed operating income in Q2 (+$0.301M) and Q3 (+$0.489M) under the new business model .
  • Liquidity progress into year-end: Cash and equivalents were $14.0M at Dec 31, up from $12.6M at Sep 30, supported by proceeds from sale of business and reduced overhead .

What Went Wrong

  • Guidance withdrawn: Management explicitly ceased providing financial guidance as it exits EP mapping/ablation and focuses on left-heart access manufacturing .
  • Discontinued operations remain a drag: FY loss from discontinued operations was $5.011M (improved vs $69.742M in 2023) but still negatively impacts total net loss .
  • Q4 operating inflection reversed: Derived Q4 operating loss of ~$0.281M (FY $(0.057)M minus 9M $0.224M) following two quarters of positive operating income; highlights sensitivity to volume/mix and non-operating items .

Financial Results

Note: Q4 2024 quarterly figures are derived from FY 2024 minus 9M (Sep 30) reported results. All values USD.

MetricQ2 2024Q3 2024Q4 2024 (derived)
Revenue ($USD Millions)$4.127 $5.266 $7.130 (20.157−13.027)
Gross Profit ($USD Millions)$(0.343) $0.372 $1.005 (1.013−0.008)
Gross Margin %−8% 7% ~14.1% (derived)
Operating Income (Loss) ($USD Millions)$0.301 $0.489 $(0.281) (−0.057−0.224)
Net Loss from Continuing Ops ($USD Millions)$(0.362) $(0.816) $(1.311) (−4.536−(−3.225))
Net Loss per Common Share ($USD)$(0.03) $(0.19) n/a (not separately disclosed)

Segment breakdown: Acutus’ revenue is exclusively from left-heart access products manufacturing/distribution to Medtronic under the Distribution Agreement; no separate segment reporting is provided .

KPIs and Balance Sheet Snapshot

KPI ($USD Millions unless noted)Q2 2024 (Jun 30)Q3 2024 (Sep 30)Q4 2024 (Dec 31)
Cash & Cash Equivalents$13.327 $12.595 $14.019
Accounts Receivable$9.235 $9.970 $7.878
Inventory$5.213 $4.191 $1.790
Long-term Debt (Current Portion)$7.055 $7.084 $7.005
Long-term Debt (Total)$25.130 $25.269 $25.564
Warrant Liability ($USD Thousands)$128 $302 $194
Cash Paid for Interest (period-to-date)$2.561 (6M) $3.394 (9M) $4.544 (FY)

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
All financial metrics (Revenue, Margin, OpEx, etc.)FY24/Q4 2024None provided in 2024 due to realignment No guidance; company will no longer provide financial guidance Maintained (no guidance)

Earnings Call Themes & Trends

Note: No Q4 2024 earnings call transcript was available. Themes reflect press releases and furnished 8-Ks.

TopicPrevious Mentions (Q2, Q3)Current Period (Q4/FY + Dec PR)Trend
Gross Margin TrajectoryQ2: −8% GAAP margin ; Q3: 7% GAAP margin FY: 5% GAAP margin; implied Q4 ~14% by derivation (FY vs 9M) Improving sequentially with higher volumes and reduced overhead
Operating LeverageQ2 and Q3 showed operating income ($0.301M; $0.489M) FY operating loss only $0.057M; Q4 derived operating loss (~$0.281M) Leverage improving on FY basis; quarterly variability persists
Strategy/RealignmentAnnounced realignment; cessation of guidance Operational downsizing (~70% workforce), focus solely on Medtronic left-heart access Accelerated exit of EP mapping/ablation; simplified model
Medtronic Earn-outsNot detailed in Q2/Q3 PRsDetailed earn-out mechanics and quarterly payments in arrears; eligibility through Jan 2027 Provides non-operating cash inflows tied to Medtronic sales
R&D ExecutionR&D essentially zero in 2024 continuing ops (Q2/Q3) FY R&D zero in continuing ops R&D curtailed under distribution-only model
Cash Burn & LiquidityOperating cash outflows (continuing ops): −$13.154M (6M) −$17.185M (FY) ; downsizing expected to reduce cash burn Cash burn elevated in 2024; reductions expected in 2025

Management Commentary

  • “Gross margin…was 5% for 2024 compared to negative 44% for 2023. The improvement was driven by higher production volumes related to left-heart access manufacturing and reduced manufacturing overhead expenses.”
  • Dr. Shaden Marzouk (Chair of the Board): “We are taking the hard but necessary steps to reduce the size of our organization while complying with our remaining obligations to Medtronic for the production of left-heart access products.”
  • CEO/CFO Takeo Mukai: “The operational downsizing impacts our team… I want to thank each one of them… These downsizing actions are expected to meaningfully reduce cash burn as well as ongoing operating expenses and are expected to be completed in the first quarter of 2025.”

Q&A Highlights

  • No Q4 2024 earnings call transcript was available; therefore, analyst Q&A themes and management responses are not provided for this period .

Estimates Context

  • Wall Street consensus estimates via S&P Global were unavailable for AFIB this quarter (GetEstimates mapping error). As a result, comparisons vs consensus EPS and revenue cannot be provided and should be considered unavailable for Q4 2024. Values would normally be retrieved from S&P Global, but data was not accessible for AFIB in this period.

Key Takeaways for Investors

  • Sequential operational execution improved through Q3 with positive operating income, and FY operating loss narrowed to essentially breakeven; Q4 shows quarterly variability, but FY trends suggest improving leverage under the Medtronic distribution model .
  • Gross margin recovery is the central fundamental driver; continued production scaling and overhead reduction are key to sustaining mid-teens quarterly margins implied in Q4 and lifting FY margins from 5% .
  • Liquidity appears adequate for near-term obligations (FY cash $14.0M), aided by sale proceeds and expected earn-outs; monitoring of debt service and working capital needs remains critical .
  • Strategic simplification: With the exit from EP mapping/ablation and ~70% downsizing, execution risk shifts to timely transition of production to Medtronic and realization of earn-outs; guidance withdrawal reduces external visibility, increasing reliance on filings cadence .
  • Short-term trading lens: Headlines around downsizing completion, any production transition milestones, and cash updates can be catalysts; absence of Street coverage may amplify volatility on incremental fundamental disclosures .
  • Medium-term thesis: Distribution-only focus can compress OpEx and stabilize margins; upside depends on Medtronic volume and earn-out performance, while downside risks include macro/clinical procedure dynamics, contract timing, and limited external guidance .
  • Discontinued operations losses have moderated dramatically (FY −$5.011M vs −$69.742M), reducing tail risk to total net loss; ongoing monitoring is warranted until fully extinguished .

Notes:

  • Q4 2024 quarterly figures are derived from reported FY 2024 and 9M 2024 results; derivations are indicated and based on cited filings .
  • No S&P Global estimates were available; estimate-based beat/miss analysis is therefore not provided this quarter.